EUCTR2008-007482-23-DE进行中（未招募）不适用
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 340
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Subjects 18 to 75 years of age, with bipolar I disorder, most recent episode depressed with or without rapid cycling disease course (= 4 episodes of mood disturbance but <8 episodes in the previous 12 months) and without psychotic features (diagnosed by DSM-IV-TR criteria, and confirmed by the MINI). The current episode of major depression associated with bipolar I disorder must be confirmed by the investigator and noted in the source records.
- •- Subjects must have a lifetime history of at least one bipolar manic or mixed manic episode. It is strongly recommended that a reliable informant (e.g., family member or caregiver) be available to confirm this history
- •-Subject’s current major depressive episode is = 4 weeks and less than 12 months in duration
- •- MADRS total score = 20 (at both screening and baseline visits)
- •- YMRS total score = 12 (at both screening and baseline visits)
- •- Lithium or divalproex levels must be within the protocol-defined therapeutic range (0.6-1.2 mEq/L for lithium or 50-125 ug/mL for divalproex) at screening. Although
- •the lower limit for lithium serum concentration is 0.6 mEq/L at screening and during
- •the study, lithium levels = 0.4 mEq/L will be permitted with Medical Monitor approval
- •if 0.6 mEq/L or higher is judged to be intolerable or unsafe for an individual subject.
- •The investigator will verify that the subject has had continuous treatment with either
- •medication for a minimum of 28 days prior to the screening visit based on
- •confirmation from a reliable informant (eg, family member or other caregiver) or
- •treating health professional.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Diagnosis of an Axis I or Axis II disorder, other than bipolar I disorder, that is the primary
- •focus of treatment within 3 months prior to screening
- •- Subject scores = 4 on MADRS item number 10 (suicidal thoughts) at screening or baseline
- •- History of non-response to an adequate (6-week) trial of three or more antidepressants (with or without mood stabilizers) during the current episode
- •- Imminent risk of suicide or injury to self, others, or property
- •- Subject has been hospitalized for a manic or mixed episode within the 60 days prior to randomization
研究者
相似试验
进行中（未招募）
1 期
uradisone for the treatment of depression disorderEUCTR2012-004132-33-GBSunovion Pharmaceuticals Inc.209
进行中（未招募）
1 期
A 6-Week Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar DepressioBipolar depressionMedDRA version: 14.1Level: LLTClassification code 10004936Term: Bipolar depressionSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2008-007482-23-CZSunovion Pharmaceuticals, Inc.340
进行中（未招募）
1 期
A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel-Group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I DepressioBipolar depressionMedDRA version: 9.1Level: LLTClassification code 10004936Term: Bipolar depressionEUCTR2008-007482-23-FRDainippon Sumitomo Pharma America Inc.340
已完成
3 期
A study to evaluate the efficacy of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression in Subjects Demonstrating Non-Response to Treatment with Lithium or Divalproex AloneCTRI/2011/06/001808Sunovion Pharmaceuticals Inc340
已完成
3 期
This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe for the treatment of patients with bipolar I depressioCTRI/2009/091/000647Dainippon Sumitomo Pharma America Inc